177 related articles for article (PubMed ID: 34654826)
1. CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties.
Vlaming M; Bilemjian V; Freile JÁ; Lourens HJ; van Rooij N; Huls G; van Meerten T; de Bruyn M; Bremer E
Sci Rep; 2021 Oct; 11(1):20499. PubMed ID: 34654826
[TBL] [Abstract][Full Text] [Related]
2. CD20
de Bruyn M; Wiersma VR; Wouters MC; Samplonius DF; Klip HG; Helfrich W; Nijman HW; Eggleton P; Bremer E
Oncoimmunology; 2015 Apr; 4(4):e999536. PubMed ID: 26137418
[TBL] [Abstract][Full Text] [Related]
3. CD8
Fiocca Vernengo F; Beccaria CG; Araujo Furlan CL; Tosello Boari J; Almada L; Gorosito Serrán M; Gazzoni Y; Montes CL; Acosta Rodríguez EV; Gruppi A
mBio; 2020 May; 11(3):. PubMed ID: 32398312
[TBL] [Abstract][Full Text] [Related]
4. CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia.
Guo L; Kapur R; Aslam R; Speck ER; Zufferey A; Zhao Y; Kim M; Lazarus AH; Ni H; Semple JW
Blood; 2016 Feb; 127(6):735-8. PubMed ID: 26556550
[TBL] [Abstract][Full Text] [Related]
5. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
[TBL] [Abstract][Full Text] [Related]
6. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
Grube M; Rezvani K; Wiestner A; Fujiwara H; Sconocchia G; Melenhorst JJ; Hensel N; Marti GE; Kwak LW; Wilson W; Barrett JA
Clin Cancer Res; 2004 Feb; 10(3):1047-56. PubMed ID: 14871984
[TBL] [Abstract][Full Text] [Related]
7. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic profile of CD3+CD20+ T cells in progressive multiple sclerosis.
Boldrini VO; Quintiliano RPS; Silva LS; Damasceno A; Santos LMB; Farias AS
Mult Scler Relat Disord; 2021 Jul; 52():103013. PubMed ID: 34030100
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 therapy depletes activated myelin-specific CD8
Sabatino JJ; Wilson MR; Calabresi PA; Hauser SL; Schneck JP; Zamvil SS
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25800-25807. PubMed ID: 31748274
[TBL] [Abstract][Full Text] [Related]
10. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
[TBL] [Abstract][Full Text] [Related]
11. B Cell Depletion With an Anti-CD20 Antibody Enhances Alloreactive Memory T Cell Responses After Transplantation.
Marino J; Paster JT; Trowell A; Maxwell L; Briggs KH; Crosby Bertorini P; Benichou G
Am J Transplant; 2016 Feb; 16(2):672-8. PubMed ID: 26552037
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
[TBL] [Abstract][Full Text] [Related]
13. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
Wang J; Press OW; Lindgren CG; Greenberg P; Riddell S; Qian X; Laugen C; Raubitschek A; Forman SJ; Jensen MC
Mol Ther; 2004 Apr; 9(4):577-86. PubMed ID: 15093188
[TBL] [Abstract][Full Text] [Related]
14. Depletion of functionally active CD20+ T cells by rituximab treatment.
Wilk E; Witte T; Marquardt N; Horvath T; Kalippke K; Scholz K; Wilke N; Schmidt RE; Jacobs R
Arthritis Rheum; 2009 Dec; 60(12):3563-71. PubMed ID: 19950291
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab.
Serra-Peinado C; Grau-Expósito J; Luque-Ballesteros L; Astorga-Gamaza A; Navarro J; Gallego-Rodriguez J; Martin M; Curran A; Burgos J; Ribera E; Raventós B; Willekens R; Torrella A; Planas B; Badía R; Garcia F; Castellví J; Genescà M; Falcó V; Buzon MJ
Nat Commun; 2019 Aug; 10(1):3705. PubMed ID: 31420544
[TBL] [Abstract][Full Text] [Related]
16. CD3
Chen Q; Yuan S; Sun H; Peng L
Hum Immunol; 2019 Mar; 80(3):191-194. PubMed ID: 30639700
[TBL] [Abstract][Full Text] [Related]
17. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
18. Dissection of a circulating CD3
Niu J; Zhai Z; Hao F; Zhang Y; Song Z; Zhong H
Clin Exp Immunol; 2018 May; 192(2):206-212. PubMed ID: 29377068
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous CD20-positive T-cell lymphoma.
Martin B; Stefanato C; Whittaker S; Robson A
J Cutan Pathol; 2011 Aug; 38(8):663-9. PubMed ID: 21623866
[TBL] [Abstract][Full Text] [Related]
20. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
